PMA device
Mitroflow Aortic Pericardial Heart Valve
Corcym Canada Corp · Heart-Valve, Non-Allograft Tissue (LWR, Class III) · First FDA decision Oct 9, 2012, newest Nov 21, 2019Aortic stenosisMitral regurgitationTricuspid regurgitation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
PMA pathway
Device trials
3
Naming "Mitroflow"
MAUDE reports
516
Brand "Mitroflow", since 2015
PubMed studies
230
Mentioning "Mitroflow"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Mitroflow Aortic Pericardial Heart Valve
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- Mitroflow Aortic Pericardial Heart ValvePMA supplement
P060038-S033 · Decided Nov 21, 2019 · 227 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
P060038-S021 · Decided Nov 25, 2014 · 64 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
- MITROFLOW AORTIC PERICARDIAL HEART VALVE WITH PHOSPHOLIPID REDUCTION TREATMENT, MODEL DLPMA supplement
P060038-S020 · Decided Jul 15, 2014 · 60 days after receipt · Normal 180 Day Track No User Fee
Device type: heart-valve, non-allograft tissue (LWR) · Cardiology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Mitroflow", any status and sponsor, newest update first.
LivaNovaPublic (LIVN)
NCT02351726 · 186 participants · Start Mar 2015 · Primary completion Dec 31, 2019
Device: Mitroflow DL · For: Aortic Stenosis; Aortic Regurgitation; Aortic Valve Insufficiency and 6 more
Sites: Los Angeles, California; San Diego, California; Jacksonville, Florida · 13 sites in all
- Randomized Sizing and Hemodynamic Study Mitroflow vs. MagnaPivotal-lookingTerminated
Sorin Group USA, Inc.Not on our public-company list
NCT00705913 · 368 participants · Start Jun 2008 · Primary completion Sep 2011
Device: Mitroflow Aortic Pericardial Heart Valve (CarboMedics); Carpentier-Edwards Magna Tissue Valve · For: Aortic Valve Disease
Sites: San Diego, California; Tampa, Florida; Kansas City, Kansas · 12 sites in all
Sorin Group USA, Inc.Not on our public-company list
NCT00630916 · 756 participants · Start Nov 2003 · Primary completion Dec 2005
Device: Mitroflow Aortic Heart Valve · For: Heart Valve Diseases
Sites: Phoenix, Arizona; Tucson, Arizona; San Diego, California · 26 sites in all
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Mitroflow", and for the whole product code for context.
This brand
516 reports: 18 malfunction, 420 injury, 76 death
Whole product code LWR
17,256 reports: 871 malfunction, 15,439 injury, 934 death
Newest reports for this brand
- MITROFLOW 12AInjury
3004478276-2025-00179 · Received Oct 10, 2025 · Event dated Apr 2, 2025
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Degraded
Patient problem as coded: Insufficient Information
3004478276-2024-00176 · Received Oct 11, 2024 · Event dated May 18, 2016
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
3019892983-2024-01015 · Received Oct 11, 2024 · Event dated May 18, 2016
Device type: Heart-Valve, Non-Allograft Tissue (LWR)
Device problem as coded: Insufficient Device Problem Information
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Mitroflow"[tiab]. The summary above synthesizes these.
- Mitroflow aortic pericardial bioprosthesis--clinical performance.
Jamieson WR, Koerfer R, Yankah CA, et al. · Eur J Cardiothorac Surg · 2009Evaluation Study, Multicenter Study
- Mitroflow Pericardial Bioprosthesis: Can a Bad Reputation Be Mitigated?
Bortolotti U · Ann Thorac Surg · 2024Letter, Comment
- Excess Reintervention With Mitroflow Prosthesis for Aortic Valve Replacement: Ten-Year Outcomes of a Randomized Trial.
Cangut B, Schaff HV, Suri RM, et al. · Ann Thorac Surg · 2023Randomized Controlled Trial
- Treating Mitroflow dysfunction by means of an open valve-in-valve Perceval implantation.
Trombetti D, Pisano C, Altieri C, et al. · Kardiochir Torakochirurgia Pol · 2023
- The Mitroflow aortic valve: A past, present, and future illuminated.
Balsam LB, DeAnda A · J Thorac Cardiovasc Surg · 2017Editorial, Comment
- Mitroflow and Perimount Magna 10 years outcomes a direct propensity match analysis to assess reintervention rates and long follow-up mortality.
Theologou T, Harky A, Shaw M, et al. · J Card Surg · 2019Observational Study
- Long-term results of the Mitroflow aortic pericardial bioprosthesis in over 800 patients: limited durability and mechanisms of dysfunction.
Ius F, Schulz J, Roumieh M, et al. · Eur J Cardiothorac Surg · 2017
- Rosuvastatin attenuates bioprosthetic heart valve calcification.
Lee S, Kim DH, Youn YN, et al. · J Thorac Cardiovasc Surg · 2019Video-Audio Media
- Structural valve degeneration of bioprosthetic aortic valves: A network meta-analysis.
Squiers JJ, Robinson NB, Audisio K, et al. · J Thorac Cardiovasc Surg · 2023Research Support, Non-U.S. Gov't, Network Meta-Analysis
- Comparison of Long-term Performance of Bioprosthetic Aortic Valves in Sweden From 2003 to 2018.
Persson M, Glaser N, Nilsson J, et al. · JAMA Netw Open · 2022Comparative Study, Research Support, Non-U.S. Gov't
- Structural valve deterioration in the Mitroflow biological heart valve prosthesis.
Issa IF, Poulsen SH, Waziri F, et al. · Eur J Cardiothorac Surg · 2018
- Durability of the Mitroflow Pericardial Prosthesis: Influence of Patient-Prosthesis Mismatch and New Anticalcification Treatment.
Blasi S, Ravenni G, Celiento M, et al. · Thorac Cardiovasc Surg · 2020
Other devices of this type
Also filed under product code LWR.
- Edwards Pericardial Aortic Bioprosthesis and INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2022
- St. Jude Medical Biocor and Biocor Supra ValvesAbbott Medical · PMA 2012
- INSPIRIS RESILIA Aortic ValveEdwards Lifesciences, LLC · PMA 2026
- TRIFORMIS RESILIA Tricuspid ValveEdwards Lifesciences, LLC · PMA 2026
- Perceval Sutureless Heart Valve, Perceval Plus Sutureless Heart ValveCorcym S.r.l. · PMA 2025
- Sjm Biocor Valve / Sjm Biocor Supra ValveAbbott Medical · PMA 2016
- Ats 3F Aortic Bioprosthesis Model 1000Medtronic, Inc. · PMA 2019
- Freestyle Aortic Root BioprosthesisMedtronic, Inc. · PMA 2013
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.